CCMI
DNLI icon

Creative Capital Management Investments’s Denali Therapeutics DNLI Stock Holding History

Creative Capital Management Investments’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463 Buy
+18
New +$370 ﹤0.01% 1285

Other funds holding DNLI

EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $833M AUM 22.71% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

Creative Capital Management Investments's DNLI Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 18 shares worth $463. The stake represents ﹤0.01% of the portfolio and ranks #1285 among its holdings.

38 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Creative Capital Management Investments held 18 shares of Denali Therapeutics worth $463 as of Q2 2026.
  • Denali Therapeutics was a new Creative Capital Management Investments position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1285 holding.
  • 38 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.